ReviewCurrent neuropharmacology2021
Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review.
Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Energy stress activates AMPK to suppress ferroptosis in neurodegenerative proteinopathies.International journal of molecular medicine · 2026Article
- Metabolite profiling, enzyme inhibition, and in silico analysis of Commiphora gileadensis oleo-gum resin.Die Naturwissenschaften · 2026Article
- Blood Metabolomic Profiling of Systemic Responses to Dried Black Lychee in a Scopolamine-Induced Cognitive Impairment in Rats.Biology · 2026Article
- Olive Components (Biophenols or Polyphenols) in Neurodegenerative Disease Models and Clinical Studies: A Systematic Review of Evidence and Translational Barriers.Biomedicines · 2026Review
- Beneficial Effects ofAntioxidants (Basel, Switzerland) · 2024Article
- Therapeutic Applications of Ginseng Natural Compounds for Health Management.International journal of molecular sciences · 2023Review
- 3D QSAR based Virtual Screening of Flavonoids as Acetylcholinesterase Inhibitors.Advances in experimental medicine and biology · 2023Article
- Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022Review
- Review
- Biocomputational Screening of Natural Compounds against Acetylcholinesterase.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) affects several people worldwide and has devastating impacts on society with a limited number of approaches for its pharmacological treatment. The main causes of AD are not clear yet. However, the formation of senile plaques, neurofibrillary tangles, hyper-phosphorylation of tau protein, and disruption of redox homeostasis may cause AD. These causes have a positive correlation with oxidative stress, producing reactive ions, which are responsible for altering the physiological condition of the body.
conclusionOngoing research recommended the use of phytochemicals as acetylcholinesterase inhibitors to hinder the onset and progression of AD. The natural compound structures, including lignans, flavonoids, tannins, polyphenols, triterpenes, sterols, and alkaloids have anti-inflammatory, antioxidant, and anti-amyloidogenic properties. The purpose of this article is to provide a brief introduction to AD along with the use of natural compounds as new therapeutic approaches for its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.